Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Axitinib × 30 days × Clear all

Phase

Phase 2 5 Phase NA 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Specimen Handling 94 Magnetic Resonance Spectroscopy 71 Biopsy 62 pembrolizumab 60 Cyclophosphamide 56 fludarabine 40 Nivolumab 30 Carboplatin 30 Gemcitabine 28 Cisplatin 26 Paclitaxel 22 fludarabine phosphate 21 atezolizumab 20 Bevacizumab 19 Radiotherapy 18 Ipilimumab 18 venetoclax 17 Fluorouracil 16 Dexamethasone 16 X-Rays 15 Oxaliplatin 14 Cetuximab 14 Taxes 13 Lenalidomide 13 Rituximab 12 Radiotherapy, Intensity-Modulated 11 Leucovorin 11 Injections 11 Doxorubicin 11 Decitabine 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05017012 2026-03-27

MK-3475A-C18

Merck Sharp & Dohme LLC

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

Data powered by HemOnc (CC BY 4.0) Colophon ⚡